- Home
- ACIU vs TSI Comparison
ACIU vs TSI Comparison
Compare ACIU & TSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACIU
- TSI
- Stock Information
- Founded
- ACIU 2003
- TSI 1987
- Country
- ACIU Switzerland
- TSI United States
- Employees
- ACIU N/A
- TSI N/A
- Industry
- ACIU Biotechnology: Pharmaceutical Preparations
- TSI Investment Managers
- Sector
- ACIU Health Care
- TSI Finance
- Exchange
- ACIU Nasdaq
- TSI Nasdaq
- Market Cap
- ACIU 270.1M
- TSI 237.5M
- IPO Year
- ACIU 2016
- TSI N/A
- Fundamental
- Price
- ACIU $2.65
- TSI $4.88
- Analyst Decision
- ACIU Strong Buy
- TSI
- Analyst Count
- ACIU 2
- TSI 0
- Target Price
- ACIU $12.00
- TSI N/A
- AVG Volume (30 Days)
- ACIU 203.0K
- TSI 106.8K
- Earning Date
- ACIU 03-13-2025
- TSI 01-01-0001
- Dividend Yield
- ACIU N/A
- TSI 7.46%
- EPS Growth
- ACIU N/A
- TSI N/A
- EPS
- ACIU N/A
- TSI N/A
- Revenue
- ACIU $48,505,404.00
- TSI N/A
- Revenue This Year
- ACIU $86.78
- TSI N/A
- Revenue Next Year
- ACIU $118.22
- TSI N/A
- P/E Ratio
- ACIU N/A
- TSI N/A
- Revenue Growth
- ACIU 4097200.00
- TSI N/A
- 52 Week Low
- ACIU $2.25
- TSI $4.48
- 52 Week High
- ACIU $4.98
- TSI $4.87
- Technical
- Relative Strength Index (RSI)
- ACIU 47.51
- TSI 54.14
- Support Level
- ACIU $2.39
- TSI $4.79
- Resistance Level
- ACIU $2.74
- TSI $4.92
- Average True Range (ATR)
- ACIU 0.14
- TSI 0.04
- MACD
- ACIU 0.01
- TSI 0.01
- Stochastic Oscillator
- ACIU 56.52
- TSI 63.64
About ACIU AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses most of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
About TSI TCW Strategic Income Fund Inc.
Tcw Strategic Income Fund Inc operates as a closed-end management investment company. Its investment objective is to seek a total return comprised of current income and capital appreciation by investing in a wide range of securities. The company invests in a range of industries, such as airlines, banks, beverages, biotechnology, chemicals, computers, diversified financial services, entertainment, and others.